ImmuCell Corporation (ICCC) |
| 6.57 0.02 (0.31%) 02-27 16:00 |
| Open: | 6.54 |
| High: | 6.59 |
| Low: | 6.38 |
| Volume: | 3,136 |
| Market Cap: | 59(M) |
| PE Ratio: | 23.46 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 7.92 |
| Resistance 1: | 6.78 |
| Pivot price: | 6.51 |
| Support 1: | 6.14 |
| Support 2: | 5.75 |
| 52w High: | 7.6 |
| 52w Low: | 4.28 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| EPS | 0.280 |
| Book Value | 3.290 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.301 |
| Profit Margin (%) | 8.37 |
| Operating Margin (%) | 0.37 |
| Return on Assets (ttm) | 3.8 |
| Return on Equity (ttm) | 8.3 |
Thu, 19 Feb 2026
(ICCC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Wed, 18 Feb 2026
ImmuCell Corporation to Announce Unaudited Financial Results for Q4 and Year-End 2025 on March 4, 2026 - Quiver Quantitative
Wed, 18 Feb 2026
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 - marketscreener.com
Wed, 18 Feb 2026
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average - What's Next? - MarketBeat
Mon, 09 Feb 2026
ImmuCell directors to step down at 2026 annual meeting, board changes expected - Investing.com
Sun, 01 Feb 2026
ImmuCell Corporation (NASDAQ:ICCC) Sees Large Increase in Short Interest - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |